Panbela announces closing of approximately $15 million public offering, and regains compliance with nasdaq listing standards

Minneapolis, minn, feb. 13, 2023 (globe newswire) --   panbela therapeutics, inc. (nasdaq: pbla ), (“panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that, primarily as a result of the january 30, 2023 closing of its public offering of approximately $15 million of common stock and warrants, panbela has regained compliance with applicable listing standards of the nasdaq stock market (“nasdaq”).
PBLA Ratings Summary
PBLA Quant Ranking